Behavioral and Neuroendocrine Effects of the Partial NMDA Agonist D-cycloserine in Healthy Subjects

Berckel, Bart van

doi:10.1016/s0893-133x(96)00196-0

Cited by 42 publications

(17 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, DCS only shows an extinction effect as an adjunct, that is, when paired with behavioral training, not when given alone. DCS readily crosses the blood-brain barrier, and peak blood levels occur 1 hour after oral administration (van Berckel et al 1997). In order to pair DCS with a behavioral component to extinguish fear responses, DCS is typically administered 1 hour before therapy sessions (Norberg et al 2008).…”

Section: Dcs As An Adjunct To Psychotherapy For Ptsdmentioning

confidence: 99%

Randomized Placebo-Controlled D-Cycloserine with Cognitive Behavior Therapy for Pediatric Posttraumatic Stress

Scheeringa

Weems

2014

Journal of Child and Adolescent Psychopharmacology

View full text Add to dashboard Cite

This initial study of CBT and DCS to treat pediatric PTSD provided suggestive and preliminary evidence for more rapid symptom recovery and beneficial effects on attention, but did not show an overall greater effect for reducing PTSD symptoms. It appears that augmentation with DCS represents unique challenges in PTSD. Because PTSD involves complex, life-threatening trauma memories, as opposed to the imagined dreadful outcomes of other anxiety disorders, the use of DCS may require greater attention to how its use is coupled with exposure-based techniques. DCS may have inadvertently enhanced reconsolidation of trauma memories rather than more positive and adaptive memories. In addition, the results suggest that future research could focus on the longer-term benefits of DCS on attention and ways to capitalize on attention-enhancing therapies. ClinicalTrials.gov registry: Effect of D-cycloserine on Treatment of Posttraumatic Stress Disorder (PTSD) in Youth, #NCT01157416, http://clinicaltrials.gov/ct2/results?term=NCT01157416&Search=Search , and D-cycloserine Adjunctive Treatment for Posttraumatic Stress Disorder (PTSD) in Adolescents, #NCT01157429, http://clinicaltrials.gov/ct2/results?term=NCT01157429&Search=Search .

show abstract

Section: Dcs As An Adjunct To Psychotherapy For Ptsdmentioning

confidence: 99%

Randomized Placebo-Controlled D-Cycloserine with Cognitive Behavior Therapy for Pediatric Posttraumatic Stress

Scheeringa

Weems

2014

Journal of Child and Adolescent Psychopharmacology

View full text Add to dashboard Cite

show abstract

“…Preclinical data suggest that cycloserine has a dose-dependent biphasic effect; at low doses (< 150 mg/d), it behaves as an agonist, whereas at higher doses (> 500 mg/d), it has an antagonist effect at the NMDA receptor. Van Berckel et al [32,33] found that at doses of 15, 50, and 150 mg/d, cycloserine was unsuccessful in eliciting neuroendocrine response as evaluated by cortisol, prolactin, and luteinizing hormone plasma levels in healthy volunteers. Conversely, 500 mg/d did increase luteinizing hormone plasma levels, but not that of cortisol and prolactin.…”

Section: Partial Agonists At the Glycine Site On The Nmda Receptor: Cmentioning

confidence: 99%

The role of glutamate in mood disorders: Results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects

Maeng¹,

Zarate²

2007

Curr Psychiatry Rep

207

143

View full text Add to dashboard Cite

In this article, we first review a study showing that the N-methyl-D-aspartate (NMDA) receptor antagonist ketamine leads to rapid, robust, and relatively sustained antidepressant effects in patients with treatment-resistant major depression. We then discuss our hypothesis that the therapeutic effects of monoaminergic antidepressants and ketamine may be mediated by increased AMPA-to-NMDA glutamate receptor throughput in critical neuronal circuits. We hypothesize that ketamine directly mediates this throughput, whereas monoaminergic antidepressants work indirectly and gradually; this may explain, in part, the lag of onset of several weeks to months that is observed with traditional antidepressants.

show abstract

“…The medication (D-cycloserine 50 mg or placebo [PLAC]) was administered orally under supervision. Peak plasma levels of D-cycloserine are reached between 90-120 min (Van Berckel et al 1997), so participants were able to read or work before baseline measures. In addition, before the start of the study, participants completed the following questionnaires-the Spielberger State and Trait Anxiety Inventory (SSAI, STAI; Spielberger 1983), the Beck Depression Inventory (BDI; Beck et al 1988) and the Anxiety Sensitivity Index (ASI; Reiss et al 1986).…”

Section: Study Design and Proceduresmentioning

confidence: 99%

“…Each participant received one capsule 90 min before baseline measures and the study procedure. Oral D- cycloserine is readily absorbed and shows a dose-related increase in plasma concentration (Van Berckel et al 1997).…”

Section: Manikin Taskmentioning

confidence: 99%

d-Cycloserine and performance under different states of anxiety in healthy volunteers

et al. 2007

View full text Add to dashboard Cite

We have shown that at lower anxiety levels, D-cycloserine 50 mg improved the performance of this challenging visuospatial cognitive task. This increase in performance was not seen when anxiety was higher, and D-cycloserine did not appear to increase subjective anxiety. These data lend support to the use of D-cycloserine and related glutamate enhancers as cognitive modulators and suggest that the actions of D-cycloserine are not simply related to increased arousal or anxiety.

show abstract

Behavioral and Neuroendocrine Effects of the Partial NMDA Agonist D-cycloserine in Healthy Subjects

Abstract: The effects of D-cycloserine, a partial agonist of the N-Methyl-D-

Cited by 42 publications

References 41 publications

Randomized Placebo-Controlled D-Cycloserine with Cognitive Behavior Therapy for Pediatric Posttraumatic Stress

Randomized Placebo-Controlled D-Cycloserine with Cognitive Behavior Therapy for Pediatric Posttraumatic Stress

The role of glutamate in mood disorders: Results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects

d-Cycloserine and performance under different states of anxiety in healthy volunteers

Contact Info

Product

Resources

About